

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ASCLETIS PHARMA INC.

歌礼制药有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1672)

VOLUNTARY ANNOUNCEMENT

**NEW DRUG APPLICATION FOR ALL-ORAL HCV
TREATMENT ACCEPTED BY CHINA FOOD AND DRUG
ADMINISTRATION**

Reference is made to the announcement of Asclepis Pharma Inc. (the “**Company**”) dated July 31, 2018 in respect of its filing of the new drug application (the “**NDA**”) for its second Category 1 HCV drug - Ravidasvir (RDV) with China Food and Drug Administration (“**CFDA**”) on July 31, 2018. The board of directors of the Company is pleased to announce that the Company received the acceptance letter from the CFDA with respect of the NDA today.

Cautionary Statement required by Rule 18A.05 of the Listing Rules of the Hong Kong Stock Exchange: We cannot guarantee that we will be able to obtain NDA approval for, or ultimately market, Ravidasvir successfully.

By Order of the Board of Directors
Asclepis Pharma Inc.
歌礼制药有限公司
Jinzi Jason WU
Chairman

Hangzhou, the People’s Republic of China
August 1, 2018

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; Mr. Wei FU, as non-executive Director; and Dr. Ru Rong JI, Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.